Please see profile under [Management].

Former Chief Executive Officer of SkyePharma PLC. He has 30 years of experience in the Pharmaceutical industry having worked for Merck, Pfizer, Purepac and most recently Faulding, where Mr. Ashton was Chairman, President and CEO.

President, Chief Executive Officer and Chairman, IBEX Technologies. Previously Executive Vice President, Sterling, Winthrop Pharmaceutical Division, New York, NY; Senior Vice President, CIBA-GEIGY Pharmaceuticals, Summit, NJ.

Mr. Henley is founder and President of Henley Capital Corporation, a boutique investment dealer specializing in financial, mergers and acquisitions and advisory services to companies covering the full spectrum of high technology. Prior to this, Mr. Henley was the head of investment banking in Toronto and ran the High Technology and Communications practice at Canada's largest independent employee-owned investment dealer. He has been an investment banker for almost 15 years and sits on a number of public and private boards of directors.

Dr. Pace is founder, director and former Chairman and CEO of QRxPharma Ltd., a development stage bio-pharmaceutical company and a Visiting Scientist at the Massachusetts Institute of Technology (MIT). He is also currently a director of ResMed Inc. (NYSE:RMD), CTour A/S, and Protiveris Inc. and is an advisor to the venture capital fund Innovation Capital. Dr. Pace is an elected Fellow of the Australian Academy of Technological Sciences and Engineering, author and co-author of over 40 research papers, reviews, and patents.

Mr. Alexopoulos has been the Secretary of the Board of Directors for Transition Therapeutics since July 1998. Mr. Alexopoulos is a Barrister and Solicitor and Partner at the law firm Sotos Associates.